BioSyent Crescita futura

Future criteri di controllo 1/6

Si prevede che BioSyent aumenterà i ricavi a una percentuale pari a 12.9% all'anno. Si prevede che l'EPS crescerà a una percentuale pari a 18.8% all'anno.

Informazioni chiave

n/a

Tasso di crescita degli utili

18.8%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili	53.4%
Tasso di crescita dei ricavi	12.9%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	21 Nov 2024

Aggiornamenti recenti sulla crescita futura

BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 19

Recent updates

BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price

Apr 14

BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 19

Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?

Mar 17

BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year

Feb 18

Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative

Jan 28

BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate

Jan 07

BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

Dec 17

Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Dec 02

Previsioni di crescita degli utili e dei ricavi

TSXV:RX - Stime future degli analisti e dati finanziari passati (CAD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2026	46	N/A	N/A	N/A	1
12/31/2025	42	N/A	N/A	N/A	1
12/31/2024	35	N/A	N/A	N/A	1
9/30/2024	35	7	2	7	N/A
6/30/2024	34	7	2	3	N/A
3/31/2024	33	7	7	7	N/A
12/31/2023	32	6	5	5	N/A
9/30/2023	31	6	6	7	N/A
6/30/2023	29	5	5	5	N/A
3/31/2023	27	5	3	4	N/A
12/31/2022	28	5	4	5	N/A
9/30/2022	28	6	4	5	N/A
6/30/2022	28	6	6	6	N/A
3/31/2022	28	6	5	5	N/A
12/31/2021	29	6	5	5	N/A
9/30/2021	27	5	5	5	N/A
6/30/2021	26	4	4	4	N/A
3/31/2021	24	4	5	6	N/A
12/31/2020	22	4	7	7	N/A
9/30/2020	22	4	10	8	N/A
6/30/2020	23	5	6	7	N/A
3/31/2020	23	5	4	5	N/A
12/31/2019	21	4	4	4	N/A
9/30/2019	22	5	1	4	N/A
6/30/2019	21	5	4	5	N/A
3/31/2019	22	6	5	6	N/A
12/31/2018	22	6	6	6	N/A
9/30/2018	22	5	6	7	N/A
6/30/2018	22	6	N/A	7	N/A
3/31/2018	21	5	N/A	7	N/A
12/31/2017	21	5	N/A	7	N/A
9/30/2017	20	5	N/A	6	N/A
6/30/2017	19	5	N/A	5	N/A
3/31/2017	18	4	N/A	5	N/A
12/31/2016	18	4	N/A	4	N/A
9/30/2016	17	4	N/A	3	N/A
6/30/2016	17	4	N/A	4	N/A
3/31/2016	16	4	N/A	4	N/A
12/31/2015	15	4	N/A	3	N/A
9/30/2015	15	4	N/A	3	N/A
6/30/2015	14	4	N/A	3	N/A
3/31/2015	13	4	N/A	3	N/A
12/31/2014	12	3	N/A	4	N/A
9/30/2014	11	3	N/A	3	N/A
6/30/2014	10	3	N/A	2	N/A
3/31/2014	9	2	N/A	2	N/A
12/31/2013	8	2	N/A	2	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Dati insufficienti per determinare se la crescita degli utili prevista RX è superiore al tasso di risparmio ( 2.3% ).

Guadagni vs Mercato: Dati insufficienti per determinare se si prevede che gli utili di RX cresceranno più velocemente del mercato Canadian

Guadagni ad alta crescita: Dati insufficienti per determinare se si prevede che gli utili di RX cresceranno in modo significativo nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di RX ( 12.9% all'anno) crescerà più rapidamente del mercato Canadian ( 7.1% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di RX ( 12.9% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di RX è previsto essere elevato tra 3 anni

BioSyent Crescita futura

Future criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target increased by 13% to CA$9.00

Price target increased to CA$10.00

Price target increased to CA$10.00

BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Recent updates

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

December 16, 2024 Declares Fourth Quarter 2024 Dividend, Payable on December 16, 2024

BioSyent Inc. to Report Q3, 2024 Results on Nov 20, 2024

BioSyent's (CVE:RX) Dividend Will Be CA$0.045

Second quarter dividend of CA$0.045 announced

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Biosyent Inc Declares Dividend for the Third Quarter of 2024, Payable on September 15, 2024

Insider recently sold CA$55k worth of stock

First quarter dividend of CA$0.045 announced

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

BioSyent Inc Declares Second Quarter 2024 Dividend, Payable June 15, 2024

BioSyent Inc. to Report Q1, 2024 Results on May 16, 2024

BioSyent's (CVE:RX) Profits May Not Reveal Underlying Issues

BioSyent Inc., Annual General Meeting, May 16, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

BioSyent Inc. to Report Q4, 2023 Results on Mar 13, 2024

Upcoming dividend of CA$0.045 per share

BioSyent (CVE:RX) Will Pay A Larger Dividend Than Last Year At CA$0.045

Third quarter dividend increased to CA$0.045

BioSyent Inc. Declares First Quarter 2024 Dividend, Payable on March 15, 2024

Upcoming dividend of CA$0.04 per share at 1.9% yield

Price target increased by 13% to CA$9.00

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

BioSyent Inc. Declares Fourth Quarter 2023 Dividend, Payable on December 15, 2023

BioSyent Inc. to Report Q3, 2023 Results on Nov 16, 2023

Second quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

BioSyent Inc. Declares Third Quarter 2023 Dividend, Payable on September 15, 2023

BioSyent Inc. to Report Q2, 2023 Results on Aug 22, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

BioSyent Inc. Declares Second Quarter 2023 Dividend, Payable on June 15, 2023

BioSyent Inc. to Report Q1, 2023 Results on May 26, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Inaugural dividend of CA$0.04 per share

BioSyent Inc. Declares Dividend for the First Quarter 2023, Payable on March 15, 2023

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target increased to CA$10.00

Insufficient new directors

BioSyent Inc. to Report Q3, 2022 Results on Nov 16, 2022

Now 21% undervalued after recent price drop

BioSyent Inc. Declares Quarterly Dividend, Payable on December 15, 2022

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

BioSyent Inc. Announces Adoption of Dividend Policy

BioSyent Inc. to Report Q2, 2022 Results on Aug 23, 2022

BioSyent Inc. to Report Q1, 2022 Results on May 18, 2022

Price target increased to CA$10.00

Insufficient new directors

Full year 2021 earnings: EPS and revenues exceed analyst expectations

BioSyent Inc. to Report Q4, 2021 Results on Mar 09, 2022

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CA$0.14 (vs CA$0.075 in 3Q 2020)

Second quarter 2021 earnings released: EPS CA$0.08 (vs CA$0.056 in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CA$0.13 (vs CA$0.11 in 1Q 2020)

BioSyent Inc.'s (CVE:RX) Intrinsic Value Is Potentially 38% Above Its Share Price

BioSyent Inc., Annual General Meeting, May 26, 2021

BioSyent Inc. (CVE:RX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Full year 2020 earnings released: EPS CA$0.29 (vs CA$0.31 in FY 2019)

Biosyent Inc. Announces Combogesic Availability in Many Pharmacies Across Canada

Declining Stock and Solid Fundamentals: Is The Market Wrong About BioSyent Inc. (CVE:RX)?

BioSyent Inc. to Report Q4, 2020 Results on Mar 17, 2021

BioSyent (CVE:RX) Shareholders Booked A 33% Gain In The Last Year

Here's Why BioSyent's (CVE:RX) Statutory Earnings Are Arguably Too Conservative

BioSyent Inc. (CVE:RX) Shares Could Be 30% Below Their Intrinsic Value Estimate

BioSyent Inc.'s (CVE:RX) Stock's On An Uptrend: Are Strong Financials Guiding The Market?

New 90-day high: CA$8.19

Investor sentiment improved over the past week

Did BioSyent Inc. (CVE:RX) Insiders Buy Up More Shares?

Revenue and earnings miss expectations

BioSyent Inc. to Report Q3, 2020 Results on Nov 26, 2020

Biosyent Inc. Announces Launch of New Feramax PD Therapeutic 150

Earnings released